MoonLake Immunotherapeutics cash flow to debt ratio of -258.90% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

MoonLake Immunotherapeutics's free cash flow has decreased 67.40% from $-117.11M last year to $-196.04M, signaling decreasing performance

MoonLake Immunotherapeutics's debt to equity ratio is 0.40, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

MoonLake Immunotherapeutics's debt has increased relative to shareholder equity from 0.01 last year to 0.40 today, signaling weakened financials

MoonLake Immunotherapeutics has negative EBITDA, making leverage ratio unreliable

MoonLake Immunotherapeutics's interest coverage ratio is -28.15, which means that the company struggles to meet interest obligations, signaling financial risk.

MoonLake Immunotherapeutics has insufficient data to evaluate this check.

MoonLake Immunotherapeutics's short-term assets of $421.69M exceed its short-term liabilities of $45.48M

MoonLake Immunotherapeutics's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

MoonLake Immunotherapeutics's return on equity of -85.61%, is lower than 15.00%, indicating bad performance

MoonLake Immunotherapeutics's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

MoonLake Immunotherapeutics had positive net income in only 0.00 out of 5 years, indicating unstable earnings

MoonLake Immunotherapeutics has negative free cash flow, indicating the company is burning cash rather than generating it

MoonLake Immunotherapeutics has negative free cash flow, indicating cash burn

MoonLake Immunotherapeutics's yearly earnings has decreased 91.13% since last year from $-118.94M to $-227.32M, signaling decreasing performance

MoonLake Immunotherapeutics's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -75.28% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

MoonLake Immunotherapeutics has insufficient revenue history to calculate 3-year revenue CAGR.

MoonLake Immunotherapeutics had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

MoonLake Immunotherapeutics had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

MoonLake Immunotherapeutics is overvalued relative to its fair value price of 2.66 based on Discounted Cash Flow model

MoonLake Immunotherapeutics has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

MoonLake Immunotherapeutics is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

MoonLake Immunotherapeutics has negative or missing EBITDA, making EV/EBITDA ratio unreliable

MoonLake Immunotherapeutics has insufficient data to evaluate this check.

MoonLake Immunotherapeutics has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

MoonLake Immunotherapeutics has a price-to-book ratio of 5.48x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

MoonLake Immunotherapeutics has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue